Manifold prediction markets as of 2026-08-13 show overwhelming market consensus (93.15% YES) that OpenAI will design...
Manifold prediction markets as of 2026-08-13 show overwhelming market consensus (93.15% YES) that OpenAI will design and manufacture a custom AI chip by 2030, while only 24.71% expect OpenAI to publicly share multi-vendor interoperability software in 2026.
confidence score
Strong evidence: 1 independent source class support this read.
signal brief
Manifold prediction markets as of 2026-08-13 show overwhelming market consensus (93.15% YES) that OpenAI will design and manufacture a custom AI chip by 2030, while only 24.71% expect OpenAI to publicly share multi-vendor interoperability software in 2026. Additionally, just 8.09% expect OpenAI to sell or rent AI compute to external customers by end-2026. Together these probabilistic signals point to an OpenAI strategy of deep vertical integration: proprietary silicon, private software stack, and compute retained for internal use rather than commoditized external sale. This is a weak signal because it reflects trader sentiment on Manifold, not an official company announcement, but the strength of the custom-chip consensus suggests the market now treats OpenAI silicon as a baseline expectation, which has implications for NVIDIA's future share of OpenAI workloads and for potential foundry partners (TSMC, Samsung) as well as HBM suppliers. The low probability of sharing multi-vendor software also implies OpenAI may not be seeking to neutralize its hardware dependence through software abstraction, making a custom chip the more likely long-term path. For AI-infrastructure and semiconductor intelligence, this is an early indicator to watch for official capex or design announcements from OpenAI in the coming quarters.
What the sources said:
- Manifold consensus on 'Will OpenAI design and manufacture a custom AI chip by 2030?': YES=93.15% (https://manifold.markets/NicholasCharette73b6/will-openai-design-and-manufacture)
- Manifold consensus on 'Will OpenAI publicly share software it developed to make its AI run on chips from different providers, in 2026?': YES=24.71% (https://manifold.markets/Bayesian/will-openai-publicly-share-software)
- Manifold consensus on 'OpenAI sells/rents AI compute to external customers by end-2026?': YES=8.09% (https://manifold.markets/RS/openai-sellsrents-ai-compute-to-ext)
source data used
“Manifold consensus on 'Will OpenAI publicly share software it developed to make its AI run on chips from different providers, in 2026?': YES=24.71%”
“Manifold consensus on 'Will OpenAI design and manufacture a custom AI chip by 2030?': YES=93.15%”
“Manifold consensus on 'OpenAI tender offer (or equivalent) before 2027-01-01 at >$20/unit?': YES=87.11%”
“Manifold consensus on 'OpenAI discovers the first proof of the Riemann Hypothesis before 2027?': YES=11.73%”
“Manifold consensus on 'Will OpenAI release its Astra model to the US general public before 2027?': YES=83.48%”
“Manifold consensus on 'Will OpenAI release a model marketed as GPT-6 by August 31, 2026?': YES=22.00%”
“Manifold consensus on 'OpenAI reaches $100B revenue in 2028?': YES=77.14%”
“Manifold consensus on 'Will any of OpenAI’s “Ten Advances in Math and Theoretical CS” be shown to be flawed by the end of August?': YES=9.93%”
“Manifold consensus on 'Will OpenAI make Astra publicly available by October 15, 2026?': YES=45.40%”
“Manifold consensus on 'OpenAI IPO before 2027?': YES=12.03%”
“Manifold consensus on 'Will OpenAI display ads to free tier users within one year?': YES=98.91%”
“Manifold consensus on 'Will OpenAI close its first day of public trading in 2026 with a market cap of $1 trillion+?': YES=21.17%”
“Manifold consensus on 'Will OpenAI broadly release a dedicated Cyber model to Trusted Access users by Sep 30, 2026?': YES=66.95%”
“Manifold consensus on 'Will OpenAI hint at or claim to have AGI by Jan 1, 2030? (1000M Subsidy)': YES=71.27%”
“Manifold consensus on 'OpenAI sells/rents AI compute to external customers by end-2026?': YES=8.09%”
Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.